Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECTAA: dapagliflozin for prevention of anthracycline-related cardiotoxicity in breast cancer
2023-506631-15-00Phase 3Authorised
- Sponsor
- 4th Military Clinical Hospital with Polyclinic
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Forxiga plus anthracycline chemotherapy with Placebo plus anthracycline chemotherapy (2 arms). Primary endpoint: Primary efficacy composite endpoint: cancer therapeutics related cardiac dysfunction. Planned start Nov 2023; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-506631-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506631-15-00.